ClinicalTrials.gg
CompletedNCT01495000Updated Feb 7, 2014Results posted

A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab

A Phase 3 interventional study of denosumab and placebo in Osteoporosis, Postmenopausal, sponsored by GlaxoSmithKline. Completed at 11 sites in India. Open to female participants aged 55 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-02-07.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
55 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies testing denosumab in Osteoporosis, Postmenopausal — 1 open to participants now, 3 under way, 2 of them phase 3. Denosumab · Osteoporosis, Postmenopausal.

Enrollment
17th of 31
250 · median 278
Started
2012
with 2 others
Phase 3
17 of 31
1 open now
Registered
12th of 31
by date
Lead sponsor
3 of 31
GlaxoSmithKline

Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, this one is the 17th largest by enrollment, is one of 3 that started in 2012, is one of 17 in phase 3, and was the 12th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 31 studies testing denosumab in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 55 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing denosumab in Osteoporosis, Postmenopausal, or all of them as a file.
02

Study summary

The purpose of this study is to determine if denosumab is effective in increasing bone mineral density at the lumbar spine in Indian postmenopausal women with osteoporosis.

03

Conditions studied

  • Osteoporosis, Postmenopausal

Keywords

  • India
  • dual energy x-ray absorptiometry
  • bone mineral density
  • denosumab
04

Who can participate

Ages eligible
55 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ambulatory Indian women with osteoporosis
  • greater than 5 years postmenopausal
  • aged 55 to 75 years old
  • absolute bone mineral density value consistent with a T-score less than -2.5 and greater than - 4.0 at the either the lumbar spine or total hip, as measured by dual energy x-ray absorptiometry. Subjects with a T-score less than or equal to -4.0 are at very high risk for fracture and will be excluded.

Exclusion criteria

Exclusion Criteria:

  • previous or current metabolic bone disease, Paget's or Cushing's disease, or hyperprolactinemia
  • current hypo- or hyperparathyroidism or hypo- or hyperthyroidism unless on stable thyroid replacement therapy and TSH level meets criteria
  • rheumatoid arthritis
  • cirrhosis of the liver or unstable liver disease or or AST greater than or equal to 2.0 times the , or alkaline phosphatase and greater than or equal to 1.5 times the upper limit of normal
  • medications used to treat osteoporosis, defined for type and duration of use, and including IV and oral bisphosphonates
  • medications that affect bone metabolism including parathyroid hormone or derivatives; anabolic steroids or testosterone; glucocorticosteroids; systemic hormone replacement therapy; selective estrogen receptor modulators; tibolone, calcitonin, and calcitriol or vitamin D derivatives; other bone active drugs including anticonvulsives (but not benzodiazepines) and heparin; chronic systemic ketoconazole, androgens, ACTH, cinacalcet, aluminum, lithium, protease inhibitors, methotrexate, and gonadotropin-releasing hormone agonists
  • within 5 years except certain resected types
  • malabsorption syndrome or gastrointestinal disorders associated with malabsorption
  • abnormal calcium level
  • vitamin D deficiency
  • any laboratory abnormality that will prevent the subject from completing the study or interferes with interpretation of study results
  • oral or dental conditions including current or past history of osteomyelitis or osteonecrosis of the jaw; active dental or jaw condition with requires oral surgery; planned invasive dental procedure; un-healed dental or oral surgery
  • any disorder that compromises the ability of the subject to give written or to comply with study procedures
  • any physical or psychiatric disorder that will prevent the subject from completing the study or interferes with study results
  • known to have tested positive for
  • less than two lumbar vertebrae evaluable for DXA measurements
  • height, weight, or girth that may preclude accurate DXA measurements
  • drug or alcohol abuse within 12 months that interferes with understanding or completing the study
  • known sensitivity to mammalian cell-derived drug products
  • use of an drug or device within 30 days of enrollment or currently receiving other investigational agent(s)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
250 participants (actual)

Study arms

  • Experimental
    Arm 1

    denosumab 60mg subcutaneous injection, single dose at the start of the 6-month double-blind treatment

    Drug: denosumab

  • Placebo comparator
    Arm 2

    placebo subcutaneous injection, single dose at the start of the 6-month double-blind treatment

    Drug: placebo

Interventions

  • 60mg subcutaneous injection, single dose

  • Drugplacebo

    placebo subcutaneous injection, single dose

06

What researchers measure

Primary outcomes

  1. Mean Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 6

    Bone mineral density (BMD) at the lumbar spine was measured by the dual-energy x-ray absorptiometry (DXA) scanner. The mean percent change from Baseline in BMD was calculated as: (value at Month 6 minus Baseline value) \* 100 / Baseline value. Analysis was performed using an Analysis of Covariance (ANCOVA) model with terms for treatment and baseline BMD at the lumbar spine (as a continuous covariate).

    Time frame: Baseline and Month 6

Secondary outcomes

  1. Mean Percent Change From Baseline in BMD at the Total Hip, Femoral Neck, and Trochanter at Month 6

    BMD at the total hip, femoral neck, and trochanter was measured by the DXA scanner. The mean percent change from Baseline in BMD was calculated as: (value at Month 6 minus Baseline value) \* 100 / Baseline value. Analysis was performed using an ANCOVA model with terms for treatment and corresponding Baseline BMD (as a continuous covariate).

    Time frame: Baseline and Month 6

  2. Median Percent Change From Baseline in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) and Serum Procollagen Type IN Propeptide (s-PINP) Markers at Months 1, 3, and 6

    Blood samples were collected for the measurement of s-CTx and s-PINP, which are used as biomarkers of bone resorption and formation, respectively. The median percent change from Baseline in s-CTX and s-PINP markers at Months 1, 3, and 6 was calculated as: (post-Baseline value minus Baseline value) \* 100 / Baseline value.

    Time frame: Baseline; Months 1, 3, and 6

  3. Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE)

    An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury with hyperbilirubinaemia. Medical or scientific judgment was to have been exercised in other important medical events. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.

    Time frame: From Baseline up to Month 6

  4. Number of Participants With a Change From Baseline in Vital Signs of Potential Clinical Concern at Months 1, 3, and 6

    Vital sign values of potential clinical concern were defined as: change in heart rate \>30 beats per minutes (bpm), change in systolic blood pressure (SBP) \>30 millimeters of mercury (mmHg), and change in diastolic blood pressure (DBP) \>20 mmHg. The number of participants with post-Baseline vital sign values of potential clinical concern who did not have values of potential clinical concern at Baseline are summarized. If the change from Baseline is a decrease greater than the threshold, it is categorized as "low." If the change from Baseline is an increase greater than the threshold, it is categorized ad "high."

    Time frame: Baseline; Months 1, 3, and 6

  5. Number of Participants With the Indicated Laboratory Parameter Values of Potential Clinical Concern at Month 6

    The number of participants with laboratory parameter values of potential clinical concern at Month 6 are summarized. The following are the laboratory values of potential clinical concern: alkaline phosphatase, High: \>375 units/Liter (L); aspartate aminotransferase, High: \>165 units/L; creatinine, High: \>159 micromoles (µmol)/L; glucose, Low: \<3 millimoles (mmol)/L; hematocrit, Low: \<0.325; hemoglobin, Low: \<91grams/L; phosphorus, High: \>1.723 mmol/L; potassium, High: \>6.3 mmol/L; sodium, Low: \<130 mmol/L; total neutrophils, Low: \<0.9 10\^9 cells (GI)/L; blood urea nitrogen (BUN), High: \>21mmol/L; uric acid, High: 654 µmol/L.

    Time frame: Month 6

  6. Change From Baseline in Albumin/Globulin Ratio and Blood Urea Nitrogen (BUN)/Creatinine Ratio at Month 6

    Blood samples were collected for the measurement of albumin/globulin ratio and BUN/creatinine ratio values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.

    Time frame: Baseline and Month 6

  7. Change From Baseline in Albumin, Hemoglobin, Mean Corpuscle Hemoglobin Concentration (Conc.), and Total Protein at Month 6

    Blood samples were collected for the measurement of albumin, hemoglobin, mean corpuscle hemoglobin concentration, and total protein values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.

    Time frame: Baseline and Month 6

  8. Change From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatinine Kinase, Gamma Glutamyl Transferase, and Lactate Dehydrogenase at Month 6

    Blood samples were collected for the measurement of alkaline phosphatase, alanine amino transferase, aspartate amino transferase, creatinine kinase, gamma glutamyl transferase, and lactate dehydrogenase values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.

    Time frame: Baseline and Month 6

  9. Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Segmented Neutrophils, Total Neutrophils, Platelet Count, and White Blood Cell Count Month 6

    Blood samples were collected for the measurement of basophil, eosinophil, lymphocyte, monocyte, segmented neutrophil, total neutrophil, platelet count, and white blood cell count values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.

    Time frame: Baseline and Month 6

  10. Change From Baseline in Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, Creatinine, and Uric Acid at Month 6

    Blood samples were collected for the measurement of direct bilirubin, indirect bilirubin, total bilirubin, creatinine, and uric acid values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.

    Time frame: Baseline and Month 6

  11. Change From Baseline in Calcium Corrected, Calcium, Chloride, Glucose, Potassium, Magnesium, Sodium, Phosphorus Inorganic, Triglycerides, Urea/BUN, and Very Low-density Lipoproteins (VLDL) Cholesterol Calculation at Month 6

    Blood samples were collected for the measurement of calcium corrected, calcium, chloride, glucose, potassium, magnesium, sodium, phosphorus inorganic, triglyceride, urea/BUN, and VLDL cholesterol calculation values. Change from Baseline was calcualted as the Month 6 value minus the Baseline value.

    Time frame: Baseline and Month 6

  12. Change From Baseline in Hematocrit at Month 6

    Blood samples were collected for the measurement of hematocrit values. Change from Baseline was calculated as the Month 6 value minuse the Baseline value.

    Time frame: Baseline and Month 6

  13. Change From Baseline in Mean Corpuscle Hemoglobin at Month 6

    Blood samples were collected for the measurement of hemoglobin values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.

    Time frame: Baseline and Month 6

  14. Change From Baseline in Mean Corpuscular Volume at Month 6

    Blood samples were collected for the measurement of mean corpuscular volume values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.

    Time frame: Baseline and Month 6

  15. Change From Baseline in Red Blood Cell Count at Month 6

    Blood samples were collected for the measurement of red blood cell count values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.

    Time frame: Baseline and Month 6

  16. Change From Baseline in Red Cell Distribution Width at Month 6

    Blood samples were collected for the measurement of red cell distribution width values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.

    Time frame: Baseline and Month 6

  17. Number of Participants With Positive and Negative Results for Anti-body Formation to Denosumab at Month 6

    The number of participants with positive and negative results for both neutralizing antibodies to denosumab and for binding antibodies to denosumab at Month 6 are summarized.

    Time frame: Month 6

07

Results

Posted Dec 25, 2013

Participant flow

Participant flow — Overall Study
MilestoneDenosumab 60 mgPlacebo
Started124126
Completed111114
Not completed1312
Withdrew: Lost to follow-up22
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject1010

Outcome measures

PrimaryMean Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 6

Bone mineral density (BMD) at the lumbar spine was measured by the dual-energy x-ray absorptiometry (DXA) scanner. The mean percent change from Baseline in BMD was calculated as: (value at Month 6 minus Baseline value) \* 100 / Baseline value. Analysis was performed using an Analysis of Covariance (ANCOVA) model with terms for treatment and baseline BMD at the lumbar spine (as a continuous covariate).

Time frame:
Baseline and Month 6
Reported as:
Least squares mean · percent change
Mean Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 6
percent changeDenosumab 60 mgPlacebo
Mean Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 64.26 ± 0.4131.20 ± 0.403
Statistical analysis
  • Denosumab 60 mg vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): 3.05 · 95% CI 1.91 to 4.19
SecondaryMean Percent Change From Baseline in BMD at the Total Hip, Femoral Neck, and Trochanter at Month 6

BMD at the total hip, femoral neck, and trochanter was measured by the DXA scanner. The mean percent change from Baseline in BMD was calculated as: (value at Month 6 minus Baseline value) \* 100 / Baseline value. Analysis was performed using an ANCOVA model with terms for treatment and corresponding Baseline BMD (as a continuous covariate).

Time frame:
Baseline and Month 6
Reported as:
Least squares mean · percent change
Mean Percent Change From Baseline in BMD at the Total Hip, Femoral Neck, and Trochanter at Month 6
percent changeDenosumab 60 mgPlacebo
Total Hip2.02 ± 0.2700.32 ± 0.271
Femoral Neck2.69 ± 0.4070.40 ± 0.409
Trochanter2.49 ± 0.3660.69 ± 0.368
SecondaryMedian Percent Change From Baseline in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) and Serum Procollagen Type IN Propeptide (s-PINP) Markers at Months 1, 3, and 6

Blood samples were collected for the measurement of s-CTx and s-PINP, which are used as biomarkers of bone resorption and formation, respectively. The median percent change from Baseline in s-CTX and s-PINP markers at Months 1, 3, and 6 was calculated as: (post-Baseline value minus Baseline value) \* 100 / Baseline value.

Time frame:
Baseline; Months 1, 3, and 6
Reported as:
Median · percent change
Median Percent Change From Baseline in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) and Serum Procollagen Type IN Propeptide (s-PINP) Markers at Months 1, 3, and 6
percent changeDenosumab 60 mgPlacebo
s-CTx, Month 1, n=112, 121-80.61 (-87.42 to -65.04)-17.01 (-40.03 to 6.93)
s-CTx, Month 3, n=107, 113-82.43 (-87.50 to -66.54)-18.97 (-44.25 to 3.56)
s-CTx, Month 6, n=105, 113-62.5 (-77.60 to -42.86)-28.82 (-47.33 to -1.15)
s-PINP, Month 1, n=110, 120-34.55 (-50.00 to -21.74)-13.62 (-23.94 to -2.21)
s-PINP, Month 3, n=107, 111-78.08 (-84.13 to -65.38)-27.87 (-42.68 to -1.75)
s-PINP, Month 6, n=104, 113-63.41 (-76.50 to -53.85)-25.81 (-41.79 to 0.00)
SecondaryNumber of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE)

An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury with hyperbilirubinaemia. Medical or scientific judgment was to have been exercised in other important medical events. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.

Time frame:
From Baseline up to Month 6
Reported as:
Number · participants
Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE)
participantsDenosumab 60 mgPlacebo
Any AE3847
Any SAE13
SecondaryNumber of Participants With a Change From Baseline in Vital Signs of Potential Clinical Concern at Months 1, 3, and 6

Vital sign values of potential clinical concern were defined as: change in heart rate \>30 beats per minutes (bpm), change in systolic blood pressure (SBP) \>30 millimeters of mercury (mmHg), and change in diastolic blood pressure (DBP) \>20 mmHg. The number of participants with post-Baseline vital sign values of potential clinical concern who did not have values of potential clinical concern at Baseline are summarized. If the change from Baseline is a decrease greater than the threshold, it is categorized as "low." If the change from Baseline is an increase greater than the threshold, it is categorized ad "high."

Time frame:
Baseline; Months 1, 3, and 6
Reported as:
Number · participants
Number of Participants With a Change From Baseline in Vital Signs of Potential Clinical Concern at Months 1, 3, and 6
participantsDenosumab 60 mgPlacebo
DBP, Month 1: High, n=122, 12512
DBP, Month 1: Low, n=122, 12514
DBP, Month 3: High, n=117, 12020
DBP, Month 3: Low, n=117, 12002
DBP, Month 6: Low, n=111, 11403
SBP, Month 1: Low, n=122, 12512
SBP, Month 3: High, n=117, 12011
SBP, Month 3: Low, n=117, 12013
SBP, Month 6: Low, n=111, 11423
Heart Rate, Month 3: Low, n=117, 12001
SecondaryNumber of Participants With the Indicated Laboratory Parameter Values of Potential Clinical Concern at Month 6

The number of participants with laboratory parameter values of potential clinical concern at Month 6 are summarized. The following are the laboratory values of potential clinical concern: alkaline phosphatase, High: \>375 units/Liter (L); aspartate aminotransferase, High: \>165 units/L; creatinine, High: \>159 micromoles (µmol)/L; glucose, Low: \<3 millimoles (mmol)/L; hematocrit, Low: \<0.325; hemoglobin, Low: \<91grams/L; phosphorus, High: \>1.723 mmol/L; potassium, High: \>6.3 mmol/L; sodium, Low: \<130 mmol/L; total neutrophils, Low: \<0.9 10\^9 cells (GI)/L; blood urea nitrogen (BUN), High: \>21mmol/L; uric acid, High: 654 µmol/L.

Time frame:
Month 6
Reported as:
Number · participants
Number of Participants With the Indicated Laboratory Parameter Values of Potential Clinical Concern at Month 6
participantsDenosumab 60 mgPlacebo
Alkaline phosphatase: High, n=107, 11401
Aspartate aminotransferase: High, n=107, 11310
Creatinine: High, n=107, 11411
Glucose: Low, n=107, 11410
Hematocrit: Low, n=106, 11111
Hemoglobin: Low, n=106, 11123
Inorganic Phosphorus: High, n=107, 11401
Potassium: High, n=107, 11310
Sodium: Low, n=107, 11401
Total Neutrophils: Low, n=104, 10702
Urea/BUN: High, n=107, 11401
Uric Acid: High, n=107, 11401
SecondaryChange From Baseline in Albumin/Globulin Ratio and Blood Urea Nitrogen (BUN)/Creatinine Ratio at Month 6

Blood samples were collected for the measurement of albumin/globulin ratio and BUN/creatinine ratio values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.

Time frame:
Baseline and Month 6
Reported as:
Mean · ratio
Change From Baseline in Albumin/Globulin Ratio and Blood Urea Nitrogen (BUN)/Creatinine Ratio at Month 6
ratioDenosumab 60 mgPlacebo
Albumin/globulin ratio0.025 ± 0.14460.018 ± 0.1518
BUN/creatinine ratio-5.896 ± 18.0195-1.860 ± 19.8400
SecondaryChange From Baseline in Albumin, Hemoglobin, Mean Corpuscle Hemoglobin Concentration (Conc.), and Total Protein at Month 6

Blood samples were collected for the measurement of albumin, hemoglobin, mean corpuscle hemoglobin concentration, and total protein values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.

Time frame:
Baseline and Month 6
Reported as:
Mean · grams per liter (g/L)
Change From Baseline in Albumin, Hemoglobin, Mean Corpuscle Hemoglobin Concentration (Conc.), and Total Protein at Month 6
grams per liter (g/L)Denosumab 60 mgPlacebo
Albumin, n=106, 1140.689 ± 2.44700.746 ± 2.9020
Hemoglobin, n=106, 1072.236 ± 6.28911.925 ± 8.4927
Mean corpuscle hemoglobin conc., n=106, 1072.321 ± 9.86531.607 ± 10.0196
Total protein, n=106, 1140.585 ± 3.82190.886 ± 4.1621
SecondaryChange From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatinine Kinase, Gamma Glutamyl Transferase, and Lactate Dehydrogenase at Month 6

Blood samples were collected for the measurement of alkaline phosphatase, alanine amino transferase, aspartate amino transferase, creatinine kinase, gamma glutamyl transferase, and lactate dehydrogenase values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.

Time frame:
Baseline and Month 6
Reported as:
Mean · International units per liter (IU/L)
Change From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatinine Kinase, Gamma Glutamyl Transferase, and Lactate Dehydrogenase at Month 6
International units per liter (IU/L)Denosumab 60 mgPlacebo
Alkaline phosphatase, n=106, 114-18.179 ± 25.0207-3.684 ± 41.4420
Alanine amino transferase, n=106, 1142.481 ± 10.24210.035 ± 15.6640
Aspartate amino transferase, 106, 1132.755 ± 10.9465-0.965 ± 16.9226
Creatinine kinase, n=106, 1146.170 ± 51.296811.175 ± 63.0331
Gamma glutamyl transferase, n=106, 1142.915 ± 12.8346-0.754 ± 13.8433
Lactate dehydrogenase, n=106, 1132.764 ± 25.28110.434 ± 36.7389
SecondaryChange From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Segmented Neutrophils, Total Neutrophils, Platelet Count, and White Blood Cell Count Month 6

Blood samples were collected for the measurement of basophil, eosinophil, lymphocyte, monocyte, segmented neutrophil, total neutrophil, platelet count, and white blood cell count values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.

Time frame:
Baseline and Month 6
Reported as:
Mean · 10^9 cells per liter (GI/L)
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Segmented Neutrophils, Total Neutrophils, Platelet Count, and White Blood Cell Count Month 6
10^9 cells per liter (GI/L)Denosumab 60 mgPlacebo
Basophils, n=104, 1030.001 ± 0.0221-0.001 ± 0.0262
Eosinophils, n=104, 103-0.076 ± 0.2794-0.001 ± 0.3414
Lymphocytes, n=104, 103-0.065 ± 0.6044-0.056 ± 0.7476
Monocytes, n=104, 1030.000 ± 0.12040.032 ± 0.1727
Segmented neutrophils, n=104, 103-0.290 ± 1.6142-0.129 ± 1.7405
Total neutrophils, n=104, 103-0.297 ± 1.6099-0.135 ± 1.7343
Platelet count, n=103, 1053.117 ± 38.53227.533 ± 36.5761
White blood cell count, n=104, 103-0.436 ± 1.6614-0.160 ± 1.7629
SecondaryChange From Baseline in Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, Creatinine, and Uric Acid at Month 6

Blood samples were collected for the measurement of direct bilirubin, indirect bilirubin, total bilirubin, creatinine, and uric acid values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.

Time frame:
Baseline and Month 6
Reported as:
Mean · micromoles per liter (UMOL/L)
Change From Baseline in Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, Creatinine, and Uric Acid at Month 6
micromoles per liter (UMOL/L)Denosumab 60 mgPlacebo
Direct bilirubin, n=105, 1120.152 ± 1.16670.089 ± 1.2122
Indirect bilirubin, n=105, 1120.210 ± 2.7305-0.054 ± 2.2050
Total bilirubin, n=106, 1140.358 ± 2.86590.000 ± 2.2102
Creatinine, n=106, 1142.337 ± 11.84583.041 ± 13.1471
Uric acid, n=106, 114-2.642 ± 60.6677-6.316 ± 61.9058
SecondaryChange From Baseline in Calcium Corrected, Calcium, Chloride, Glucose, Potassium, Magnesium, Sodium, Phosphorus Inorganic, Triglycerides, Urea/BUN, and Very Low-density Lipoproteins (VLDL) Cholesterol Calculation at Month 6

Blood samples were collected for the measurement of calcium corrected, calcium, chloride, glucose, potassium, magnesium, sodium, phosphorus inorganic, triglyceride, urea/BUN, and VLDL cholesterol calculation values. Change from Baseline was calcualted as the Month 6 value minus the Baseline value.

Time frame:
Baseline and Month 6
Reported as:
Mean · millimoles per liter (MMOL/L)
Change From Baseline in Calcium Corrected, Calcium, Chloride, Glucose, Potassium, Magnesium, Sodium, Phosphorus Inorganic, Triglycerides, Urea/BUN, and Very Low-density Lipoproteins (VLDL) Cholesterol Calculation at Month 6
millimoles per liter (MMOL/L)Denosumab 60 mgPlacebo
Calcium corrected, n=12, 240.015 ± 0.05730.008 ± 0.0755
Calcium, n=106, 1130.012 ± 0.11940.033 ± 0.1069
Chloride, n=106, 114-0.802 ± 3.0376-0.895 ± 3.0552
Glucose, n=106, 113-0.571 ± 2.2401-0.303 ± 2.6346
Potassium, n=106, 1130.140 ± 0.45810.158 ± 0.4118
Magnesium, n=106, 1140.009 ± 0.07180.009 ± 0.0614
Sodium, n=106, 114-0.472 ± 2.2979-0.395 ± 2.5921
Phosphorus inorganic, n=106, 114-0.052 ± 0.2047-0.012 ± 0.1674
Triglycerides, n=106, 114-0.305 ± 0.7413-0.263 ± 0.8433
Urea/BUN, n=106, 114-0.283 ± 1.14230.114 ± 2.2032
VLDL cholesterol calculation, n=103, 109-0.131 ± 0.3178-0.105 ± 0.3504
SecondaryChange From Baseline in Hematocrit at Month 6

Blood samples were collected for the measurement of hematocrit values. Change from Baseline was calculated as the Month 6 value minuse the Baseline value.

Time frame:
Baseline and Month 6
Reported as:
Mean · proportion of RBCs in blood
Change From Baseline in Hematocrit at Month 6
proportion of RBCs in bloodDenosumab 60 mgPlacebo
Change From Baseline in Hematocrit at Month 60.004 ± 0.02040.004 ± 0.0264
SecondaryChange From Baseline in Mean Corpuscle Hemoglobin at Month 6

Blood samples were collected for the measurement of hemoglobin values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.

Time frame:
Baseline and Month 6
Reported as:
Mean · picograms
Change From Baseline in Mean Corpuscle Hemoglobin at Month 6
picogramsDenosumab 60 mgPlacebo
Change From Baseline in Mean Corpuscle Hemoglobin at Month 60.407 ± 0.86130.260 ± 1.2787
SecondaryChange From Baseline in Mean Corpuscular Volume at Month 6

Blood samples were collected for the measurement of mean corpuscular volume values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.

Time frame:
Baseline and Month 6
Reported as:
Mean · femtoliters
Change From Baseline in Mean Corpuscular Volume at Month 6
femtolitersDenosumab 60 mgPlacebo
Change From Baseline in Mean Corpuscular Volume at Month 60.623 ± 2.97750.327 ± 3.5309
SecondaryChange From Baseline in Red Blood Cell Count at Month 6

Blood samples were collected for the measurement of red blood cell count values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.

Time frame:
Baseline and Month 6
Reported as:
Mean · 10^12 cells per liter (TI/L)
Change From Baseline in Red Blood Cell Count at Month 6
10^12 cells per liter (TI/L)Denosumab 60 mgPlacebo
Change From Baseline in Red Blood Cell Count at Month 60.016 ± 0.25750.034 ± 0.3034
SecondaryChange From Baseline in Red Cell Distribution Width at Month 6

Blood samples were collected for the measurement of red cell distribution width values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.

Time frame:
Baseline and Month 6
Reported as:
Mean · percentage
Change From Baseline in Red Cell Distribution Width at Month 6
percentageDenosumab 60 mgPlacebo
Change From Baseline in Red Cell Distribution Width at Month 60.065 ± 1.2126-0.121 ± 1.2735
SecondaryNumber of Participants With Positive and Negative Results for Anti-body Formation to Denosumab at Month 6

The number of participants with positive and negative results for both neutralizing antibodies to denosumab and for binding antibodies to denosumab at Month 6 are summarized.

Time frame:
Month 6
Reported as:
Number · participants
Number of Participants With Positive and Negative Results for Anti-body Formation to Denosumab at Month 6
participantsDenosumab 60 mgPlacebo
Neutralizing antibodies, n=0, 0NANA
Binding antibodies, Positive, n=110, 11400
Binding antibodies, Negative, n=110, 114110114

Adverse events

Collected over SAEs (serious adverse events) and non-serious AEs were collected from the start of study medication through the study period (6-month post-dose) (up to Study Week 43).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Denosumab 60 mg—1/124 (0.8%)8/124 (6.5%)
Placebo—3/126 (2.4%)3/126 (2.4%)
Most frequent serious events
Most frequent serious events
EventDenosumab 60 mgPlacebo
Cataract nuclearEye disorders1/1240/126
HypotensionVascular disorders0/1241/126
Varicose vein rupturedVascular disorders0/1241/126
AstheniaGeneral disorders0/1241/126
Liver abscessInfections and infestations0/1241/126
Hepatic enzyme increasedInvestigations0/1241/126
Most frequent other events
Most frequent other events
EventDenosumab 60 mgPlacebo
Upper respiratory tract infectionInfections and infestations8/1243/126

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Denosumab 60 mgPlaceboTotal
Mean62.6 ± 5.1062.6 ± 4.8562.6 ± 4.96
Sex: Female, Male
Sex: Female, Male(Participants)Denosumab 60 mgPlaceboTotal
Female124126250
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Denosumab 60 mgPlaceboTotal
Asian - Central/South Asian Heritage124126250
08

Study locations

11 sites
  • GSK Investigational Site
    Ahmedabad, 380015, India
  • GSK Investigational Site
    Bangalore, 560043, India
  • GSK Investigational Site
    Bangalore, 560052, India
  • GSK Investigational Site
    Bangalore, 560054, India
  • GSK Investigational Site
    Delhi, 110060, India
  • GSK Investigational Site
    Mangalore, 575002, India
  • GSK Investigational Site
    Nagpur, 440010, India
  • GSK Investigational Site
    Nagpur, 440012, India
  • GSK Investigational Site
    Pune, 411030, India
  • GSK Investigational Site
    Trivandrum, 695011, India
  • GSK Investigational Site
    Vadodra, 390007, India
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2011
First posted
Dec 19, 2011
Start
Jan 2012
Primary completionActual
Feb 2013
CompletionActual
Feb 2013
Results first posted
Dec 25, 2013
Last update
Feb 7, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01495000
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 19, 2011
Start date
Jan 2012
Primary completion
Feb 2013
Completion
Feb 2013
Results posted
Dec 25, 2013
Last update
Feb 7, 2014

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion